



## Summary of the MAQC June-30-2005 Teleconference

### **The MAQC Project: Calibrated RNA Samples, Reference Datasets, and QC Metrics/Thresholds for Microarray Quality Control**

Meeting Date: June 30, 2005 (9 am PDT / 11 am CDT / 12 pm EDT / 16:00 GMT)

Meeting Place: Teleconference

Summary Date: June 30, 2005

Author: James Fuscoe, FDA/NCTR, +1-870-543-7126, [jfuscoe@nctr.fda.gov](mailto:jfuscoe@nctr.fda.gov)

1. **Brain RNA:** Mike Wilson and Bob Setterquist were unable to attend the teleconference so no update was available.
2. **Pilot Titration Study:** Rich Shippy briefed the group on progress to date. A summary of the most recent teleconference on the pilot titration study was distributed today as a separate mailing.
3. **Sequence-based Mapping across Platforms:** Damir Herman updated the group on progress. Damir described his efforts using MegaBlast to match probe sequences to the RefSeq database. Anti-sense probes were discovered along with some probes that matched multiple RNA species. Discussion will be held off-line with the probe designers to understand the reasons for this. A white paper from Illumina describing probe design will be made available to the mapping group, as well as a list of anti-sense probes. These anti-sense probes are typically masked so that standard analysis proceeds without these data. Probe sequences from all the providers have been received by the MAQC or are in-progress. ABI lawyers are currently evaluating the form in which their sequences can be provided. A material transfer agreement is currently being worked out with Eppendorf to receive their probe sequences.
4. **Selection of Test Sites:** Each platform provider has agreed to select 3 sites for evaluation of the 2 sample RNAs in the MAQC Main Study. There was discussion on the number of test sites to be selected after Janet Warrington proposed that Affymetrix would use 6 sites. **Send comments about this issue to Jim Fuscoe (cc: Leming Shi).** The sites should be chosen for their known ability to produce high quality data because these reference datasets will be important in development of QC metrics/thresholds for microarray quality control as well as for evaluation of data analysis methods. Most of the platform providers have identified 2 or 3 sites and are on-schedule to have at least 3 sites committed by the start of the main MAQC study. Test sites will be invited to participate in the MAQC teleconferences, etc. Please provide the emails for the test sites to Jim Fuscoe (cc: Leming Shi) for inclusion in the MAQC email list.

5. **MAQC Web Site:** The MAQC website is set up and can be found at <http://www.fda.gov/nctr/science/centers/toxicoinformatics/maq/index.htm>. It was agreed that the platform providers would send recommended protocols to Jim Fuscoe (cc: Leming Shi) for posting on the web site.

The next MAQC Teleconference:

Thursday, July 14, 2005 (9 am PDT / 11 am CDT / 12 pm EDT / 16:00 GMT),

Our fearless leader Leming will be back from China.